Document is current

Article History

Received: 30 January 2025

Revised: 24 June 2025

Accepted: 25 July 2025

First Online: 21 August 2025

Declarations

:

: The experiments described in this work were conducted in agreement with the Swedish Animal Welfare Agency regulations and the EU Directive 2010/63/EU for animal experiments, and have been approved under the permission “Mechanisms of epilepsy and epileptogenesis: cell and gene therapy studies in rats and mice”, by the local Malmö and Lund ethical committee for animal research on 4 April 2020 (number 5.8.18-02998-2020). The study adheres to the ARRIVE guidelines for animal pre-clinical studies.The original source of the cell line (ATCC) has confirmed that there was initial ethical approval for collection of human cells, and that the donors had signed informed consent. The hTERT-AT-MSCs (SCRC4000) cell line used in this study was obtained from ATCC under a Material Transfer Agreement (MTA) with Lund University. ATCC ensures that all human-derived materials it distributes comply with 45 CFR 46 and relevant ethical regulations. As part of its policy, ATCC requires depositors to confirm that all human tissue samples used to establish cell lines were collected under protocols approved by an Institutional Review Board (IRB), with prior informed consent from donors or their legally authorized representatives, and with appropriate confidentiality safeguards in place. Additionally, the Material Transfer Agreement (MTA) between ATCC and our institution explicitly states that the materials provided have been collected in compliance with all applicable ethical regulations, including donor consent and confidentiality protections. Further documentation is available in the ATCC Donor Policy Letter and the MTA Agreement.

: The authors declare that they have no competing interests.